Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

被引：0
|
作者：
Nigro, O. [1 ]
Cortellini, A. [2 ]
Giusti, R. [3 ]
Marchetti, P. [3 ]
De Galitiis, F. [4 ]
Di Pietro, F. R. [4 ]
Bersanelli, M. [5 ]
Lazzarin, A. [5 ]
Galetta, D. [6 ]
Pizzutillo, P. [6 ]
Santini, D. [7 ]
Torniai, M. [8 ]
De Giglio, A. [9 ]
Russo, A. [10 ,11 ]
Silva, R. R. [12 ]
Bolzacchini, E. [13 ]
Natoli, C. [14 ]
Rijavec, E. [15 ]
Vallini, I. [1 ]
Pinotti, G. [1 ]
机构：
[1] Osped Circolo Varese, ASST Sette Laghi, Med Oncol, Varese, Italy
[2] St Salvatore Hosp, Med Oncol, Laquila, Italy
[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy
[4] IRCCS, IDI, Oncol & Oncol Dermatol, Rome, Italy
[5] Azienda Osped Univ Parma, Med Oncol, Parma, Italy
[6] Clin Canc Ctr Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy
[7] Campus Biomed, Med Oncol, Rome, Italy
[8] Univ Politecn Marche, Azienda Osped Univ Ospedali Riuniti Umberto I, Med Oncol, Ancona, Italy
[9] Osped S Maria Misericordia, Oncol Med, Perugia, Italy
[10] AO Papardo, Med Oncol, Messina, Italy
[11] Dept Human Pathol, Messina, Italy
[12] Area Vasta 2, ASUR Marche, Med Oncol, Fabriano, Italy
[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy
[14] SS Annunziata Hosp, Med Oncol, Chieti, Italy
[15] Policlin Milano, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
    Sonpavde, Guru P.
    Grivas, Petros
    Lin, Yushun
    Hennessy, Daniel
    Hunt, Jay D.
    FUTURE ONCOLOGY, 2021, 17 (19) : 2545 - 2558
  • [22] Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
    Abulizi, Adila
    Yan, Guangpeng
    Xu, Qian
    Muhetaer, Reyihanguli
    Wu, Shihan
    Abudukelimu, Kudelaiti
    Chen, Xi
    Liu, Chengjiang
    Li, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment
    Kim, Sarah
    Colevas, A. Dimitrios
    Tse, Stephanie
    On, Sandy
    Cheung, Edna
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Immune-related thyroid dysfunction in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors
    Bulusu, Venkata
    Jessop, Susan
    Paul, Sherin
    Chapman, Timothy
    Aslam, Shahzeena
    Jeffs, Yvonne
    Punnen, Geethu
    Geetha, Anil
    Hutka, Margaret
    LUNG CANCER, 2023, 178 : S30 - S30
  • [25] Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition
    Oppel-Heuchel, H.
    Grimm, M. -O.
    UROLOGE, 2016, 55 (05): : 677 - 688
  • [26] Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China
    Chen, X.
    Fang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S303 - S303
  • [27] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [28] Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition
    Goswami, Meghali
    Gui, Gege
    Lindblad, Katherine
    Del Rivero, Jaydira
    Marte, Jennifer
    Dagur, Pradeep
    Destefano, Christin
    Thompson, Julie
    Popescu, Bogdan
    Dillon, Laura
    Johnson, Cheryl
    Soldin, Steven
    Lai, Catherine
    Gulley, James
    Hourigan, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [29] Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
    Hoang, T.
    Elliot, M. J.
    Poletes, C.
    Corke, L.
    Weiss, J.
    Tsao, M. -S.
    Bradbury, P.
    Shepherd, F. A.
    Liu, G.
    Leighl, N.
    Sacher, A.
    Lau, S. C. M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S372 - S372
  • [30] Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
    Yan, Ting
    Long, Minghui
    Liu, Chaoyi
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Liao, Dehua
    FRONTIERS IN PHARMACOLOGY, 2025, 16
12345